

Index

- abdominal pain, investigation for, 147
 abscesses, bowel, 145, 147
 acoustic noise, 16–17
 acquisition time
 breast imaging, 32
 magnetic resonance angiography (MRA), 49, 62
 rectal imaging, 153
 temporal resolution and, 17
 ACTHomas, 97
 adenocarcinoma
 liver metastasis, 2
 pancreatic, 86–91, 94, 100, 107
 prostatic, 186
 adenoma
 adrenal, 112, 114–15, 116, 117
 colorectal, 145–7
 pancreatic, 100
 adhesions, bowel, 142
 adiabatic pulses, 44
 adrenal gland imaging
 adenoma, 112, 114–15, 116, 117
 adrenal incidentalomas, 111
 adrenocortical carcinoma, 117–18
 cysts, 120
 ganglioneuroma, 120–1
 hemorrhage, 120
 metastases, 113, 117
 myelolipoma, 113, 116, 119
 optimized 3T protocol, 117
 pheochromocytoma, 118–19
 techniques, 111–17, 122
 adrenal SI-to-spleen SI ratio (ASR), 113–14
 adrenocortical carcinoma, 117–18
 aneurysms
 aortic, 54, 56–60
 renal artery, 55
 angiography
 insulinoma detection, 96
 magnetic resonance (MRA),
 See magnetic resonance
 angiography (MRA)
 angiomyolipoma, 167, 172
 anorectal junction, 153
 antiperistaltic agents, 141, 198
 aorta
 aortic aneurysm, 54, 56–60
 aortitis, 58–60
 dissection of, 58
 magnetic resonance angiography (MRA), 49, 56–60
 mirror artifact from, 82
 normal, 54
 apparent diffusion coefficient (ADC)
 values
 bowel imaging, 142
 breast imaging, 31
 liver imaging, 76–7
 prostate imaging, 184, 186–8
 appendicitis, 147
 arterial spin labeling (ASL), 15, 23
 artifacts, *See also specific artifacts*
 female pelvic imaging, 197
 increase at 3T, 1, 10
 ascites, 4, 8, 14, 135, 141
 atherosclerosis, 53, 54, 55, 58, 60–1
 autoimmune pancreatitis, 109
 b-value, 185
 B0 field inhomogeneity
 bowel imaging, 135
 breast imaging, 29
 liver imaging, 67–9
 novel acquisition techniques, 13–14
 overview at 3T, 6–7
 susceptibility and, 4–5
 B1 field inhomogeneity
 bowel imaging, 135
 breast imaging, 27, 30
 cardiac magnetic resonance (CMR)
 imaging, 35–6, 37
 liver imaging, 69–70, 77
 novel acquisition techniques, 14
 overview at 3T, 7–8
 balanced steady-state free precession (bSSFP)
 bowel imaging, 136, 142, 145, 148
 cardiac magnetic resonance (CMR)
 imaging, 35, 36–9, 40
 banding artifacts
 balanced steady-state free precession (bSSFP), 35, 37–8, 136, 142
 bowel imaging, 136, 142
 cardiac magnetic resonance (CMR)
 imaging, 35, 37–8
 steady-state free precession (SSFP), 19–20
 bandwidth
 adrenal imaging, 117
 chemical shift increase
 counteraction, 5
 kidney MR imaging, 166
 magnetic resonance angiography (MRA), 49
 magnetic resonance urography, 173
 barium
 enema use, 134
 fecal tagging use, 138
 follow-through examinations, 134
 biliary-enteric anastomoses, 127, 129
 biopsy
 breast, 32
 prostate, 178, 180, 189, 190–2
 black hole artifact, 8
 bladder cancer (urothelial carcinoma), 173, 176
 blood oxygen level-dependent (BOLD) technique, 16
 blooming, 4
 blurring artifacts, 71, 166, 173, 175
 bolus timing, magnetic resonance angiography (MRA), 51
 bone metastases, 160
 bowel gas, susceptibility artifacts, 170, 175
 bowel imaging
 1.5T versus 3T, 147–8
 adhesions, 142
 artifacts at 3T, 134–6, 137–8
 colorectal polyps and colorectal cancer (CRC), 145–7, 147–8
 currently unstudied indications, 147
 historical developments in, 134
 inflammatory bowel disease (IBD)/ Crohn's disease, 142–5, 147, 148
 patient preparation, 136–40
 recommended scan parameters, 141
 sequences at 3T, 140–2
 bowel motion artifact, 141, 198–9
 brain tumors, gadolinium contrast effects, 2
 breast imaging
 1.5T and 3T protocols' comparison, 32
 3T literature review, 28
 addressing specific challenges of 3T, 28–31
 advanced functional MR imaging techniques, 31
 advantages of 3T, 26
 biopsy guidance, 32
 clinical perspective, 31–2
 clinical utility of, 26
 summary, 32–3
 breath-hold instructions
 bowel imaging, 140
 compliance difficulties, 104, 106
 capillary blush, 83, 104
 carbon dioxide (CO₂), rectal insufflation, 137, 138, 139
 carcinoid tumors, 98, 147
 cardiac magnetic resonance (CMR) imaging
 cine sequences, 40
 first pass perfusion, 41–2
 myocardial delayed enhancement (MDE), 42–4
 myocardial tagging, 40–1

- summary of 3T benefits, 44–6
- technical considerations at 3T, 34–40
- uses of, 34
- celiac disease, 147
- cervical cancer, 200
- chemical shift
 - adrenal gland imaging, 111–15, 119, 121
 - bowel imaging, 138
 - cardiac magnetic resonance (CMR) imaging, 35, 37, 38–9
 - female pelvic imaging, 197, 200, 202
 - liver imaging, 68–9, 71–5
 - magnetic resonance angiography (MRA), 49
 - magnetic resonance spectroscopy (MR spectroscopy), 12
 - novel acquisition techniques, 12, 18–19
 - overview of effects at 3T, 5–6
 - renal imaging, 170–1
- chemoradiation (CRT), rectal cancer, 150, 157–9
- cholangiocarcinoma, 3, 124, 126, 127–8
- cholecystitis, acute, 129
- choledochal cysts, 126
- cholelithiasis, 104, 106
- choline levels
 - breast tumors, 31
 - prostate cancer, 184, 188–9
- Churg–Strauss syndrome, 43
- cine imaging
 - bowel, 142, 143
 - cardiac, 40
- circumferential resection margin (CRM), rectal cancer, 156
- cirrhosis, 3, 72, 74, 76–7
- citrate, 182, 184, 188–9
- collision tumor, 117
- colorectal cancer (CRC)
 - adrenal metastasis, 113
 - etiology of, 150
 - detection at 1.5T versus 3T, 147–8
 - incidence of, 150
 - liver metastasis, 2, 78
 - MR colonography, 145–7
 - rectal cancer staging, 150, 155–7, 159, 161
 - restaging rectal cancer after chemoradiation (CRT), 157–9
 - total mesorectal excision (TME), 150–1, 156
 - treatment stratification in rectal cancer, 150–1
 - whole-body staging, 159–61
- colorectal polyps, 140, 145–8
- comb sign, 143
- common bile duct (CBD), 83, 84, 90, 107, 127
- computer-aided detection (CAD) post-processing programs, 32
- contrast-enhanced imaging
 - adrenal, 116, 118, 120
 - bowel, 136–40, 143, 145
 - cardiac magnetic resonance (CMR), 35, 41–3
 - differences at 3T, 2, 15
 - dynamic, *See* dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
 - female pelvic, 202
 - gadolinium-based contrast agents, *See* gadolinium-based contrast agents
 - iron-containing contrast agents, *See* iron-containing contrast agents
 - kidney MR imaging, 165, 166, 169–70
 - liver, 71, 75, 78
 - magnetic resonance (MR) urography, 173, 174–6
 - magnetic resonance angiography (MRA), *See* magnetic resonance angiography (MRA)
 - magnetic resonance cholangiopancreatography (MRCP), 125, 131
 - pancreas, *See* pancreas imaging
 - rectal, 152, 156
- contrast-to-noise ratio (CNR)
 - breast imaging, 28
 - cardiac magnetic resonance (CMR) imaging, 40, 41, 42, 43–4
 - liver imaging, 72
 - magnetic resonance cholangiopancreatography (MRCP), 124
 - T1 relaxation times and, 15
- creatine, 182, 184, 188–9
- creeping fat, 144
- Crohn’s disease, 142–5, 147, 148
- CT (computed tomography) imaging
 - bowel, 134, 145, 146
 - colorectal cancer (CRC) whole-body imaging, 159–61
 - multi-detector row (MDCT), 111
 - pancreas, 90, 104, 107
 - urography, 176
- cystadenocarcinoma
 - mucinous, 100
 - serous, 99
- cystadenoma
 - mucinous, 100
 - serous, 103–4
- cysts
 - adrenal, 120
 - hemorrhagic, 167, 169
 - liver, 97
 - ovarian, 197
 - renal, 165, 166, 168, 171
- dephasing, 13
- desmoplasia, 155, 159
- dielectric pad, 8, 69, 70
- dielectric shading/standing wave artifact
 - bowel imaging, 141
 - cardiac magnetic resonance (CMR) imaging, 35–6
 - liver imaging, 4, 69–70
 - novel acquisition techniques, 14
 - overview at 3T, 7–8
- diffusion tensor imaging (DTI), 187
- diffusion-weighted imaging (DWI)
 - bowel, 135, 142
 - breast, 26, 31
 - colorectal cancer (CRC) whole-body imaging, 159–61
 - dephasing in, 13
 - female pelvic, 200, 202
 - liver, 75, 76–7
 - overview of, 23
 - prostate, 183–8, 190, 191
 - renal, 165, 166, 168, 170
 - urinary tract, 165
- digital rectal examination (DRE), prostate cancer screening, 178
- diverticular disease, 147
- Dixon method, two-point, 115–16
- double duct sign, 130
- duct of Santorini, 86
- duct of Wirsung, 86
- duodenum, *See also* bowel imaging
 - pancreatic cancer invasion, 92
 - ulceration, 95
- duty cycle, 9
- dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
 - adrenal, 118
 - bowel, 148
 - female pelvic, 200, 202
 - liver, 77
 - prostate, 183, 189–90
- dynamic magnetic resonance imaging
 - contrast-enhanced, *See* dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)
 - pelvic floor dysfunction, 202–4
- dysplasia, 140
- echo planar imaging (EPI)
 - bowel, 135
 - liver, 67, 76–7
 - prostate, 183–8, 191
 - susceptibility artifacts, 4, 15
- echo time (TE)
 - adrenal imaging, 114, 117, 121
 - bowel imaging, 135, 138, 141
 - breast imaging, 32
 - chemical shift effects and, 5–6, 12
 - field inhomogeneity limitation, 7
 - in- and opposed-phase differences at 3T and 1.5T, 18–19
 - kidney MR imaging, 166
 - liver imaging, 67–9, 71, 73–4, 75

Index

- echo time (TE) (cont.)
 magnetic resonance angiography (MRA), 49
 magnetic resonance urography, 173, 174
 pancreas imaging, 83
 prostate imaging, 180
 rectal imaging, 153
 echo train length (ETL)
 liver imaging, 67, 71
 rectal imaging, 153
 echo-train spin-echo sequences
 pancreas imaging, 83
 single-shot, *See* single-shot echo-train spin-echo
 EKG-gating, magnetic resonance angiography (MRA), 62
 endocrine tumors, 91–8
 endoleaks, 58
 endometrial carcinoma, 200–2
 endometriosis, 204
 endorectal coils, 21, 179–80, 188
 endorectal ultrasound (EUS), 159
 enteroclysis, 134, *See also* magnetic resonance enteroclysis
 eosinophilic myocarditis, 43
 European Crohn's and Colitis Organisation (ECCO), current guidelines, 143
 FAME (Fast acquisition multiecho), 141
 fast low-angle shot (FLASH), 40,
 See also spoiled gradient echo
 fast spin echo (FSE)
 bowel imaging, 135
 female pelvic imaging, 199
 liver imaging, 71, 76
 rectal imaging, *See* rectal imaging
 single-shot, *See* single-shot fast spin echo (SSFSE)
 fat
 creeping, 144
 macroscopic, 167
 fat-only (FO) images, 113, 115–16, 120, 121
 fat saturation, *See also* fat suppression
 bowel imaging, 140, 141, 144, 145, 146
 chemical shift effects and, 12
 magnetic resonance angiography (MRA) developments, 62
 fat suppression
 adrenal gland imaging, 119
 bowel imaging, 141, 143, 144
 chemical shift effects and, 5
 female pelvic imaging, 197, 200, 202, 204
 kidney MR imaging, 165, 166, 167
 liver imaging, 71–5, 76
 MR urography, 173, 174
 pancreas imaging, 82–3, *See* pancreas imaging
 prostate imaging, 183
 rectal imaging, 151, 152
 renal imaging, 168
 single-shot partial fourier T2, 19
 three-dimensional acquisitions, 17
 fat–water misregistration
 balanced steady-state free precession (bSSFP), 38–9
 fecal tagging, 138–40
 female pelvic imaging
 adnexal mass, 204
 advantages and disadvantages of 3T, 197–9
 gynecologic malignancy, 200–2
 pelvic floor dysfunction, 202–4
 sequences for, 199–200
 ferritin, 73
 fibro fatty proliferation, 144
 fibroadenomas, 28
 fibroids, uterine, 200
 fibromuscular dysplasia (FMD), 54, 55
 fibrosis
 after chemoradiation (CRT), 158–9
 bowel, 143
 liver, 76–7
 nephrogenic systemic (NSF), 2, 52, 175
 pancreatic, 107, 109
 field inhomogeneity
 B0 field, *See* B0 field inhomogeneity
 B1 field, *See* B1 field inhomogeneity
 field of view (FOV)
 adrenal imaging, 117
 bowel imaging, 134, 141
 breast imaging, 32
 magnetic resonance angiography (MRA), 49, 62
 pancreas imaging, 83
 prostate imaging, 180
 rectal imaging, 151, 152, 153
 FIESTA (fast imaging employing steady-state acquisition), 40, 135,
 See also balanced steady-state free precession (bSSFP)
 fistulae, bowel, 145, 147
 flip angle
 adrenal imaging, 115, 117
 balanced steady-state free precession (bSSFP), 36–7, 38
 bowel imaging, 141
 breast imaging, 32
 cardiac magnetic resonance (CMR) imaging, 35, 36–7, 38, 44
 kidney MR imaging, 166
 liver imaging, 71, 73, 74, 75
 magnetic resonance angiography (MRA), 49
 magnetic resonance urography, 173
 pancreas imaging, 83
 prostate imaging, 180
 specific absorption rate (SAR) and, 9, 15
 steady-state free precession (SSFP), 19
 focal nodular hyperplasia (FNH), 76
 functional magnetic resonance imaging (fMRI), *See also specific techniques*
 breast, 26, 31
 magnetic resonance angiography (MRA), 62
 magnetic susceptibility, 5
 prostate, 179, 184, 190, 191
 furosemide, 173, 174, 175
 gadobutrol, 52, 53, 58
 gadodiamide, 52
 gadofosveset, 52, 58, 62
 gadolinium-based contrast agents,
 See also specific agents
 bowel imaging, 136
 kidney MR imaging, 170
 liver imaging, 72, 76, 77, 78
 magnetic resonance angiography (MRA), 53, 58, 62
 magnetic resonance urography, 176
 relaxation rates at 3T, 2, 15, 35
 gadoteridol, 53
 gadoxetic acid, 125
 ganglioneuroma, 120–1
 gastrinomas, 92, 94–5
 Gd-BOPTA, 52, 53, 58
 Gd-DOTA, 53
 Gd-DTPA, 52
 ghosting artifacts, 13
 glucagon, 141, 180
 glucagonomas, 97
 gradient echo (GRE) imaging
 adrenal glands, *See* adrenal gland imaging
 bowel, 135, 144, 145
 female pelvic, 200
 kidney MR imaging, 164, 166, 168–9, 172
 liver, 67, 71, 74, 75
 MR urography, 173, 175
 multiecho, 74
 overview of 2D T1-weighted, 18–19
 susceptibility artifacts, 4, 15, 67
 GRAPPA, 49, 50–1
 half-Fourier acquisition single-shot turbo spin-echo (HASTE)
 adrenal imaging, 117, 119
 benefits of 3T, 3
 magnetic resonance cholangiopancreatography (MRCP), 124
 pancreas imaging, 83
 prostate imaging, 180
 half-Fourier RARE (rapid acquisition relaxation enhancement), 83
 hemangioma, 76
 hematocrit effect, 167
 hematuria, 176
 hemochromatosis, 24, 67, 73

Index

- hemorrhage
 - adrenal, 118, 120
 - pancreatic, 104, 107
 - post-prostate biopsy, 180, 189
- hemorrhagic cysts, 167, 169
- hemorrhagic necrotizing
 - pancreatitis, 107
- hemosiderin, 73, 169, 170
- hemosiderosis, 67
- hepatic arteries, 61
- hepatic steatosis, 108
- hepatitis B, 73
- hepatocellular carcinoma (HCC), 4, 74, 76, 77
- hydronephrosis, 165
- hypercholes, 71
- hyperplasia, pancreatic, 100
- hypertrophic cardiomyopathy (HCM), 41
- ileal jejunization, 147
- ileocolonoscopy, 143
- imaging volume, 9, 48
- implanted medical devices, safety
 - issues, 9
- India ink artifact
 - balanced steady-state free precession (bSSFP), 38–9
 - cardiac magnetic resonance (CMR) imaging, 38–9
 - increased magnetic field strength and, 5
 - kidney MR imaging, 171, 172
 - novel acquisition techniques, 18
- insulinomas, 91–4, 95–7
- internal iliac artery, 153
- intersectional gap
 - adrenal imaging, 117
 - bowel imaging, 141
 - liver imaging, 75
 - pancreas imaging, 83
- intraductal papillary mucinous neoplasms (IPMNs), 100–3, 131–2
- intrahepatic bile duct, 124
- inversion recovery
 - phase-sensitive (PSIR), 43
 - preparatory pulses, 1
 - spectral attenuated (SPAIR), 19–20
 - spoiled gradient recalled acquisition in the steady state (IR-SPGR) method, 43
- inversion time (TI), 43–4
- iodinated contrast agent, fecal tagging, 138–40
- iron
 - fat-only (FO) images in presence of, 116
 - liver storage, 4, 24, 73, 74, 75
- iron-containing contrast agents, 5, 67, 76, 157, 175
- islet cell tumors, 91–8
- isotropic voxels, 47, 55
- iterative decomposition of water and fat
 - with echo asymmetry and least-squares estimation (IDEAL) method, 74
- jejunum, *See also* bowel imaging
 - bile duct anastomosis, 127
 - ulceration, 95
- kidney
 - chemical shift artifact, 5
 - horseshoe, 165
 - imaging, *See* renal imaging
 - magnetic susceptibility artifact, 7
 - multilocular cystic nephroma, 167
 - organ transplantation, 55
 - renal arteries, *See* renal arteries
 - renal cell carcinoma, 167, 168, 169
- kinetic curves, breast imaging, 32
- Larmor frequency, 5, 12, 35
- LAVA (liver acquisition with volume acceleration), 58, 59, 61, 72
- lightbulb sign, 118
- lipid fraction, quantification of, 18
- liver imaging
 - applications in focal and diffuse liver disease, 75–7
 - cirrhosis, 3, 72, 74, 76–7
 - cysts, 97
 - fibrosis, 76–7
 - future directions, 77
 - hepatic steatosis, 108
 - hepatocellular carcinoma (HCC), 4, 74, 77
 - iron deposition, 4, 24, 73, 74, 75
 - LAVA (liver acquisition with volume acceleration), 58, 59, 61, 72
 - metastases, *See* liver metastases
 - opportunities and challenges at 3T, 67–71
 - optimized protocol for, 75
 - organ transplantation, 130
 - sequence optimization at 3T, 71–5
 - susceptibility-weighted imaging (SWI), 23–4
 - T1 relaxation times, 2
- liver metastases
 - 1.5T and 3T, imaging differences, 2, 4
 - adrenocortical carcinoma, 118
 - colorectal cancer (CRC), 2, 78, 159, 160
 - ovarian cancer, 202
 - pancreatic cystic neoplasms, 97
 - pancreatic endocrine tumors, 96, 97, 98
- lung imaging, 21, 160
- lymph nodes
 - inflammatory bowel disease (IBD) imaging, 145
 - pancreatic cancer metastases, 90–1
 - rectal cancer staging, 156–7, 159, 161
 - whole-body imaging, 160, 161
- lymphoma, bowel, 147
- macroscopic fat, 167
- magnetic resonance angiography (MRA)
 - aorta and iliac vessels' imaging, 56–60
 - benefits of 3T, 21, 24, 47–9
 - contrast agents for abdominal, 51–3
 - contrast-to-noise ratio (CNR) increase in, 2
 - dephasing in, 13
 - future directions, 62
 - imaging protocol for abdominal contrast-enhanced (CE-MRA), 49–51
 - mesenteric arteries, 60–2
 - non-contrast-enhanced (NCE-MRA), 53–4
 - renal artery imaging, 54–6, 62
 - uses of abdominal/pelvic, 47
- magnetic resonance
 - cholangiopancreatography (MRCP)
 - 3T and 1.5T comparison, 124–5
 - acute cholecystitis, 129
 - advantages over other imaging techniques, 123
 - anatomical variant and congenital anomaly, 125–6
 - cholangiocarcinoma, 127–8
 - choledocolithiasis, 126–7
 - intraductal papillary mucinous neoplasms (IPMNs), 101–3, 131–2
 - normal pancreas, 84
 - overview at 3T, 20–1, 123–4
 - pancreas divisum, 86
 - pancreatic cancer, 130–1
 - pancreatitis, 108, 109, 129–30
 - postoperative pancreaticobiliary tract alterations, 129
 - primary sclerosing cholangitis (PSC), 129
 - secretin-enhanced, 109
 - techniques, 125
 - uses of, 82, 83
- magnetic resonance colonography, 137–40, 145–7
- magnetic resonance colonoscopy, 143
- magnetic resonance elastography (MRE), 24
- magnetic resonance enteroclysis, 136–7, 143
- magnetic resonance enterography, 136–7, 142, 143
- magnetic resonance spectroscopic imaging (MRSI), prostate, 181, 188–9, 190
- magnetic resonance spectroscopy (MR spectroscopy)
 - 3T advantages, 21
 - breast, 26, 31
 - chemical shift effects, 5, 12
 - female pelvic imaging, 197, 202
 - liver imaging, 68, 75
 - spatial resolution increase in, 17

Index

- magnetic resonance tagging, 40–1
- magnetic resonance urography, 165, 172–7
- magnetization preparation pulses, 1
- mannitol, 136
- Marfan's syndrome, 57
- matrix
- adrenal imaging, 117
 - bowel imaging, 141
 - breast imaging, 32
 - liver imaging, 75
 - magnetic resonance angiography (MRA), 49
 - pancreas imaging, 83
 - prostate imaging, 180
 - rectal imaging, 153
- mesenteric ischemia, 60–1
- mesenteric vessels, 49, 53, 59, 60–2, 153
- mesorectal fascia (MRF), 152, 153, 155, 156
- mesorectum, 153
- total mesorectal excision (TME), 150–1, 156
- metastatic disease
- adrenal gland, 113, 117
 - bone, 160
 - liver, *See* liver metastases
 - lung, 160
 - lymph nodes, 90–1
 - whole-body imaging, 159–61
- microcystic adenoma, 103–4
- mirror artifact, pancreas imaging, 82
- motion artifacts
- bowel imaging, 141
 - female pelvic imaging, 198–9
 - magnetic resonance angiography (MRA), 47
 - prostate imaging, 179, 180
- mucinous cystic neoplasm, 100
- multi-detector row computed tomography (MDCT), 111
- muscularis propria, 153, 154, 155, 159
- myelolipoma, 113, 116, 119
- myocardial delayed enhancement (MDE), 42–4
- myocardial tagging, 40–1
- N-butyl scopolamine bromide, 141
- necrosis
- adrenal gland, 118
 - pancreatic, 97, 104–7
- nephrogenic systemic fibrosis (NSF), 2, 52, 175
- nephroma, 167
- nonalcoholic steatohepatitis (NASH), 74
- NSA (number of signal averages), 141, 153
- off-resonance contrast angiography (ORCA), 62
- organ transplantation, 55, 130
- Ormond's disease, 58
- ovaries, *See also* female pelvic imaging
- adnexal mass, 204
 - cysts, 197
 - ovarian cancer, 202
- pancreas imaging
- adenocarcinoma, 86–91, 94, 100, 107
 - cystic neoplasms, 98–104
 - endocrine tumors, 91–8
 - imaging parameters, 83
 - intraductal papillary mucinous neoplasms (IPMNs), 131–2
 - normal pancreas findings, 83
 - pancreas divisum, 83–6
 - pancreatic cancer, 130–1
 - pancreatitis, 88–90, 104–9, 129–30
 - technique and advantages at 3T, 82–3
- parallel imaging (PI)
- breast, 29, 32
 - cardiac, 39–40
 - female pelvic, 197
 - kidney MR imaging, 164, 166
 - liver imaging, 67, 70, 71, 77
 - magnetic resonance angiography (MRA), 49, 50–1, 60, 62
 - magnetic resonance urography, 173
 - novel acquisition techniques, 16
 - prostate, 187
- parallel RF transmission, 30
- pediatric imaging, 21
- pelvic floor dysfunction, 202–4
- pelvic imaging
- female, *See* female pelvic imaging
 - magnetic resonance angiography (MRA), *See* magnetic resonance angiography (MRA)
 - rectum, 151–3
- perinephric fluid, 171
- peristalsis
- antiperistaltic agents, 141, 198
 - bowel, 141, 180, 198
 - ureteral, 175
- peritoneal reflection, 153, 154
- peritoneal tumor metastases, 160
- peritumoral stranding, 155
- Peutz–Jeghers syndrome, 147
- phase cancellation artifact, *See* India ink artifact
- pheochromocytoma, 118–19
- polyamine, 188–9
- polyethylene glycol (PEG) electrolyte, 138
- polyps, colorectal, 140, 145–8
- portal vein, 90
- positron emission tomography (PET)
- adrenal gland imaging, 111
 - colorectal cancer (CRC) whole-body imaging, 159–61
- post-processing filters, 70
- precession/Larmor frequency, 5, 12, 35
- pregnancy, MR urography in, 174
- primary biliary cirrhosis, 109
- primary sclerosing cholangitis (PSC), 109, 129
- PROPELLER (periodically rotated overlapping parallel lines with enhanced reconstruction), 77
- prostate cancer
- biopsy guidance, 190–2
 - current treatment options, 179
 - imaging of, *See* prostate imaging
 - incidence rates, 178
 - screening and diagnosis, 178
- prostate imaging
- advantages of magnetic resonance imaging, 179
 - background information on prostate cancer, 178–9
 - benefits of 3T, 18, 21
 - biopsy guidance, 190–2
 - diffusion-weighted (DWI), 183–8, 190, 191
 - dynamic contrast-enhanced MR imaging (DCE-MRI), 189–90
 - endorectal coil use, 21, 179–80, 188
 - magnetic resonance spectroscopic imaging (MRSI), 181, 188–9, 190
 - morphologic, 180–1
 - T2-weighted, 180–3, 190, 191
 - transrectal ultrasonography (TRUS), 178, 190–1
- prostate-specific antigen (PSA), 178
- prostatic hyperplasia, 178
- prostatitis, 178
- pseudocysts, pancreatic, 105–7
- pulmonary emboli, 21
- radiofrequency (RF) coils
- breast, 28, 32
 - liver imaging, 70
 - prostate imaging, 21, 179–80, 186, 187, 188, 191
 - recent advances in, 8
- radiofrequency (RF) cushion/dielectric pad, 8, 69, 70
- radiofrequency (RF) excitation pulses, 70
- radiofrequency (RF) heating, specific absorption rate (SAR) and, 14–15
- radiofrequency (RF) transmission, parallel, 30
- radiofrequency (RF) wavelength, B1 field inhomogeneity and, 14
- radiotherapy
- chemoradiation (CRT), 150, 157–9
 - rectal cancer, 150
- rapid acquisition relaxation enhancement (RARE), 124
- rectal cancer, *See* colorectal cancer (CRC), rectal imaging

- rectal imaging
 3T protocol, 151–2
 anatomy, 153–5
 background to, 150–1
 endorectal ultrasound (EUS), 159
 image quality, 153
 recommendations, 161
 rectal cancer restaging after
 chemoradiation (CRT), 157–9
 rectal insufflation, 137–8, 139
 rectal vessels, 153
 rectosigmoid junction, 153
 renal arteries
 aneurysm, 55
 magnetic resonance angiography
 (MRA), 47, 54–6, 62
 renal artery stenosis (RAS), 54–6, 62
 renal cell carcinoma, 167, 168, 169–70
 renal imaging
 kidney MR imaging, 164–72
 MR urography, 172–7
 renal arteries, *See* renal arteries
 use of, 164
 renal transplant, 55
 repetition time (TR)
 3T requirements, 1
 adrenal imaging, 117
 banding artifacts' reduction in bSSFP
 imaging, 37–8
 bowel imaging, 135, 141
 breast imaging, 32
 kidney MR imaging, 166
 liver imaging, 71, 75
 magnetic resonance angiography
 (MRA), 49
 magnetic resonance urography, 173
 pancreas imaging, 83
 prostate imaging, 180
 rectal imaging, 153
 respiratory gating, 62
 respiratory motion artifact, 4, 47
 respiratory triggering, 19, 20, 124
 Riolan's anastomosis, 53
 safety considerations, 9
 sarcoma, uterine, 200
 secretin-enhanced magnetic resonance
 cholangiopancreatography
 (MRCP), 109
 section thickness
 adrenal imaging, 117
 bowel imaging, 141
 breast imaging, 32
 magnetic resonance
 cholangiopancreatography
 (MRCP), 125
 pancreas imaging, 83, 125
 prostate imaging, 180
 rectal imaging, 151, 153
 sensitivity encoding (SENSE), 16,
 50–1
 serous cystadenocarcinoma, 99
 serous cystadenoma, 103–4
 shading artifacts, renal imaging, 171
 shim^{ing}
 balanced steady-state free precession
 (bSSFP) imaging, 38
 bowel imaging, 135
 breast imaging, 29
 cardiac magnetic resonance (CMR)
 imaging, 38
 liver imaging, 67
 SI index (SII), 113–14, 115
 signal intensity–time curves, 2, 42, 44
 signal-to-noise ratio (SNR)
 balanced steady-state free precession
 (bSSFP), 40
 bandwidth increase and, 5
 bowel imaging, 141
 breast imaging, 28
 cardiac magnetic resonance (CMR)
 imaging, 34, 39–40, 41, 42, 43–4
 diffusion-weighted imaging
 (DWI), 185
 female pelvic imaging, 197
 higher magnetic field strength and, 1,
 2, 3, 12–13
 liver imaging, 71, 73
 magnetic resonance spectroscopy
 (MRS) and increased, 21
 parallel imaging, 39–40
 spoiled gradient echo, 40
 urinary tract imaging, 164, 177
 simultaneous acquisition of spatial
 harmonics (SMASH), 16
 single-shot echo-train spin-echo
 kidney MR imaging, 166
 lymph node metastases, 93
 MR urography, 173
 normal pancreas, 84
 pancreatic adenocarcinoma,
 88, 93
 pancreatic cystic neoplasms, 101
 pancreatic endocrine tumors,
 94, 96
 pancreatitis, 104, 105, 106, 107
 single-shot fast spin echo (SSFSE)
 benefits of 3T, 3
 bowel imaging, 135, 141, 143,
 145, 148
 female pelvic imaging, 199
 liver imaging, 70, 74, 75, 76
 magnetic resonance
 cholangiopancreatography
 (MRCP), 20–1
 renal imaging, 167, 171, 172
 single-shot partial Fourier T2, 19
 siting issues, 9
 Sjögren syndrome, 109
 sodium phosphate, 138
 solid pseudopapillary tumor, 104–9
 somatostatinomas, 97
 sorbitol, 137
 SPACE sequence, 71, 199
 spasmolytic agents, 151, 180
 spatial resolution
 breast imaging, 28, 31–2
 cardiac magnetic resonance (CMR)
 imaging, 43–4
 female pelvic imaging, 197
 kidney MR imaging, 165–6
 magnetic resonance angiography
 (MRA), 47, 49, 50
 novel acquisition techniques, 17
 specific absorption rate (SAR)
 bowel imaging, 135, 141
 breast imaging, 28–9
 cardiac magnetic resonance (CMR)
 imaging, 35, 36
 female pelvic imaging, 197
 liver imaging, 70–1
 magnetic resonance angiography
 (MRA), 51
 novel acquisition techniques, 13, 14–15
 overview at 3T, 8–9
 spectral attenuated inversion recovery
 (SPAIR) technique, 19–20
 spin echo (SE) imaging, 15, 135,
See also fast spin echo (FSE); turbo
 spin echo (TSE)
 spoiled gradient echo
 cardiac magnetic resonance (CMR)
 imaging, 40
 liver imaging, 78
 pancreas imaging, 82, 83
 standing wave artifact/dielectric shading
 bowel imaging, 141
 cardiac magnetic resonance (CMR)
 imaging, 35–6
 liver imaging, 4, 69–70
 novel acquisition techniques, 14
 overview at 3T, 7–8
 steady-state free precession (SSFP),
 19–20, 53, 77
 balanced, *See* balanced steady-state
 free precession (bSSFP)
 stenosis
 bowel, 143–4
 renal artery (RAS), 54–6, 62
 stent, ureteral, 174
 superior mesenteric artery (SMA), 90,
 92, 109
 superior mesenteric vein (SMV), 90,
 92, 131
 superparamagnetic iron oxide (SPIO), 5,
 67, 76
 ultrasmall particles (USPIO), 76, 157
 susceptibility artifacts
 bowel imaging, 135, 137
 breast imaging, 29, 32
 cardiac magnetic resonance (CMR)
 imaging, 35
 diffusion-weighted imaging (DWI),
 6–7, 22, 161
 fat suppression breakdown, 20
 female pelvic imaging, 198

Cambridge University Press

978-0-521-19486-0 - Body MR Imaging at 3 Tesla

Edited by Ihab R. Kamel and Elmar M. Merkle

Index

[More information](#)

Index

- susceptibility artifacts (cont.)
 kidney MR imaging, 170
 liver imaging, 3, 68–9, 73, 76
 magnetic resonance urography, 174
 magnetic resonance
 cholangiopancreatography (MRCP), 21, 124
 novel acquisition techniques, 15–16
 overview at 3T, 2–5
 prostate imaging, 180
 three-dimensional T1-weighted GRE imaging, 18
 susceptibility-weighted imaging (SWI), 16, 23–4, 67
- T1 relaxation times
 bowel imaging, 134, 137
 breast imaging, 27, 30
 cardiac magnetic resonance (CMR) imaging, 34–5, 42
 liver imaging, 71, 75
 magnetic resonance angiography (MRA), 48
 novel acquisition techniques, 15
 overview at 3T, 1–2
 prostate imaging, 180
 renal imaging, 167–8
- T2 relaxation times
 bowel imaging, 134
 cardiac magnetic resonance (CMR) imaging, 34–5
 liver imaging, 71
 novel acquisition techniques, 15–16
 overview at 3T, 2–3
 prostate imaging, 180
- T2* relaxation times, 3–5, 67, 68
 Takayasu disease, 59, 60
 temporal resolution, 17, 28
 three-dimensional gradient echo (3D GRE) imaging
 adrenal, 114–16, 117, 121
 bowel, 138, 139, 140, 141, 148
 breast, 27, 29
 kidney MR imaging, 167
 liver, 72, 75
 magnetic resonance angiography (MRA), 21
 magnetic resonance urography, 165, 175
- overview of T1-weighted, 17–18
 pancreas, *See* pancreas imaging
 THRIVE (T1 high-resolution isotropic volume examination)
 aortic imaging, 58, 59, 61
 bowel imaging, 141
 liver imaging, 3–4
 time of flight (TOF), liver imaging, 75
 total mesorectal excision (TME), 150–1, 156
 transrectal ultrasonography (TRUS), 178, 190–1
 TRAPS (smooth transitions between psuedo steady states), 71
 TRICKS (time-resolved imaging of contrast-kinetics), 57
 trueFISP (true fast imaging with steady-state free precession), 40, 135, 191, *See also* balanced steady-state free precession (bSSFP)
 tumor tissue, T1 relaxation times, 2
 turbo spin echo (TSE)
 female pelvic imaging, 199
 half-Fourier acquisition single-shot, *See* half-Fourier acquisition single-shot turbo spin echo (HASTE)
 liver imaging, 71
 magnetic resonance
 cholangiopancreatography (MRCP), 20, 124, 127, 130
 prostate imaging, 183
 three-dimensional, 3, 20, 71, 124, 130, 199
 two-point Dixon method, 112, 115–16
 TWSIT (time-resolved MRA with stochastic interleaved trajectories), 57
- ulceration, bowel, 145
 ulcerative colitis, 142, 143
 ultrasmall superparamagnetic particles of iron oxide (USPIO), 76, 157
 ultrasound
 bowel, 134
 endorectal (EUS), 159
 transrectal ultrasonography (TRUS), 178, 190–1
 ureter
 imaging of, *See* urinary tract imaging
 ureteral calculi, 175
- ureteral stent, 174
 urinary tract imaging
 congenital anomalies, 176
 hematuria evaluation, 176
 kidney MR imaging, 164–72
 MR urography, 172–7
 ureteral calculi, 175
 urothelial carcinoma (bladder cancer), 165, 173, 176
 use of, 164
 urothelial carcinoma (bladder cancer), 165, 173, 176
 uterus, *See also* female pelvic imaging
 adnexal mass, 204
 bowel motion artifact, 198
 cervical cancer, 200
 endometrial carcinoma, 201
 endometriosis, 204
 fibroids and sarcoma differentiation, 200
 normal, 198
- vascular encasement, pancreatic cancer, 90
 VERSE (variable-rate selective excitation) sequences, 15, 71
 VIBE (volumetric interpolated breath-hold examination) sequences
 bowel imaging, 141
 liver imaging, 3–4, 58, 61, 72
 magnetic resonance angiography (MRA), 59
 pancreas imaging, 83
 VIPomas, 97
 von Hippel–Lindau disease, 98
 voxel size
 breast imaging, 32
 magnetic resonance angiography (MRA), 49
- water excitation magnetization-prepared rapid acquisition gradient-echo (WE-MPRAGE), 104
 water-only (WO) images, 115
 water, bowel imaging use, 136, 138
 whole-body imaging, 159–61
 Zollinger–Ellison syndrome, 95